Teva Pharmaceutical Industries Limited (0LER.IL)

13.12 +0.32 (+2.54%) At close: 06:58PM BST

Teva Pharmaceutical Industries Limited

124 Dvora Hanevi’a Street
Tel Aviv 6944020
Israel
972 3 914 8213
https://www.tevapharm.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 34,004

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Eliyahu Sharon Kalif	Exec. VP & CFO	2.01M	N/A	1973
Mr. Eric Drape	Exec. VP of Global Operations	1.91M	N/A	1962
Mr. Mark Sabag	Exec. VP of International Markets Commercial	1.92M	N/A	1971
Dr. Sven Dethlefs Ph.D.	Exec. VP of North America Commercial	1.76M	N/A	1969
Mr. Richard D. Francis	Pres, CEO & Director	N/A	N/A	1968
Mr. Amir Weiss	Sr. VP & Chief Accounting Officer	N/A	N/A	1977
Ran Meir	Head of Investor Relations	N/A	N/A	N/A
Mr. David M. Stark	Exec. VP & Chief Legal Officer	N/A	N/A	1969
Kathleen Veit	Sr. VP, Global Compliance & Ethics Officer	N/A	N/A	N/A
Ms. Vikki Conway	Acting Head of Global HR	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia, as well as a collaboration with Sanofi to co-develop and co-commercialize TEV-48574 asset, a novel anti-TL1A therapy for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Corporate governance

Teva Pharmaceutical Industries Limited’s ISS governance QualityScore as of 1 October 2023 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.